Auransa Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Later Stage VC
- Investors
-
7
Auransa General Information
Description
Developer of a biology-first AI platform designed to discover novel therapeutics using human disease data. The company offers a proprietary data-driven discovery engine that analyzes large-scale gene expression datasets and clinical insights, enabling oncology research teams to identify targeted therapies and advance precision medicine programs.
Contact Information
Website
www.auransa.comCorporate Office
- 1726 Edgewood Drive
- Palo Alto, CA 94303
- United States
Corporate Office
- 1726 Edgewood Drive
- Palo Alto, CA 94303
- United States
Auransa Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 04-Jan-2023 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC (Series A) | 15-Oct-2021 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series A) | 31-May-2017 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 22-Dec-2014 | $2.81M | $2.81M | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
Auransa Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A4 | ||||||||
| Series A3 | ||||||||
| Series A2 | ||||||||
| Series A1 | ||||||||
| Series A | 3,019,703 | $0.000100 | $0.37 | $4.68 | $4.68 | 1x | $4.68 | 16.49% |
| Seed | 2,810,000 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 15.34% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Auransa Patents
Auransa Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025189166-A1 | Pharmaceutical compounds for treatment of bipolar disorder | Pending | 07-Mar-2024 | ||
| WO-2025189166-A8 | Pharmaceutical compounds for treatment of bipolar disorder | Pending | 07-Mar-2024 | ||
| EP-4688745-A2 | Pentamidine analogue polymorphs, formulations, and methods thereof | Pending | 07-Apr-2023 | ||
| US-20260274798-A1 | Pentamidine analogue polymorphs, formulations, and methods thereof | Pending | 07-Apr-2023 | ||
| WO-2024211870-A2 | Pentamidine analogue polymorphs, formulations, and methods thereof | Inactive | 07-Apr-2023 | C07D213/81 |
Auransa Signals
Auransa Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Harmonix Fund | Venture Capital | Minority | ||
| 11.2 Capital | Venture Capital | Minority | ||
| AME Cloud Ventures | Venture Capital | Minority | ||
| DCVC | Venture Capital | Minority | ||
| Lux Capital | Venture Capital | Minority |
Auransa FAQs
-
When was Auransa founded?
Auransa was founded in 2014.
-
Where is Auransa headquartered?
Auransa is headquartered in Palo Alto, CA.
-
What is the size of Auransa?
Auransa has 11 total employees.
-
What industry is Auransa in?
Auransa’s primary industry is Discovery Tools (Healthcare).
-
Is Auransa a private or public company?
Auransa is a Private company.
-
What is Auransa’s current revenue?
The current revenue for Auransa is .
-
How much funding has Auransa raised over time?
Auransa has raised $26.5M.
-
Who are Auransa’s investors?
Harmonix Fund, 11.2 Capital, AME Cloud Ventures, DCVC, and Lux Capital are 5 of 7 investors who have invested in Auransa.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process